What Are Semaglutides? Breaking Down the Buzzword
Wondering what semaglutides are? Get a simple breakdown of the medications, how they work, and how Eden connects you to licensed providers for evaluation.
Wondering what semaglutides are? Get a simple breakdown of the medications, how they work, and how Eden connects you to licensed providers for evaluation.
This content is for informational purposes only and does not constitute medical advice. Semaglutide is only prescribed when clinically appropriate and is dispensed through state-licensed pharmacies. Eden is not a pharmacy or a healthcare provider. Eden connects individuals with licensed providers for evaluation and care coordination.
The word “semaglutides” seems to be everywhere; in headlines, wellness forums, and even on social media. But what exactly are semaglutides? Are they all the same thing, or just part of a bigger trend in metabolic health?
In this article, we’ll clarify what the term “semaglutides” really refers to, why it’s gained traction in the health and wellness space, and how Eden helps you connect with independent, licensed providers to determine whether a semaglutide-based treatment may be clinically appropriate for your needs.
The term “semaglutides” is not a medical term; it’s a popular shorthand used to refer to medications that contain the active compound semaglutide. These include:
All three medications contain semaglutide but differ in indication, dose, and delivery method.
Semaglutide is part of a class of medications known as GLP-1 receptor agonists. It works by mimicking a naturally occurring hormone (GLP-1) that affects several key metabolic functions, including:
Semaglutide was first introduced in the U.S. in 2017 and has since become one of the most widely prescribed medications in its class, especially as awareness of metabolic health continues to grow.
{{primary-cta}}
The growing conversation around “semaglutides” can be attributed to:
But it’s important to keep in mind that semaglutide medications are prescription-only, and they’re not appropriate for everyone. A licensed provider must evaluate your full medical history to determine clinical eligibility.
*The STEP 2 trial used FDA-approved semaglutide (Ozempic®), a once-weekly injectable formulation manufactured by Novo Nordisk and approved for the treatment of type 2 diabetes.
No, while they share the same active ingredient, formulations of semaglutide differ in several ways:
A provider will recommend the appropriate format based on your health history, diagnosis, and personal preferences.
{{primary-cta}}
Like any medication, semaglutide may come with potential side effects. The most commonly reported include:
Clinical trials suggest that these symptoms often occur during dose escalation and may improve over time. For long-term use, providers typically monitor lab values, weight trends, and side effect tolerance. The GLP-1 formulation used in the referenced study is the same active ingredient as in FDA-approved Wegovy® for chronic weight management.
Eden is a digital health platform that supports access to care in metabolic health, skincare, and haircare. Eden does not manufacture medications, write prescriptions, or operate as a pharmacy.
Instead, Eden:
Whether you're curious about pills or injections, Eden helps you explore semaglutide options with a qualified provider who can assess your needs.
“Semaglutides” might be a buzzword, but what really matters is understanding the medical science and clinical guidance behind the trend. Whether prescribed as Ozempic®, Wegovy®, or Rybelsus®, semaglutide-based treatments are not one-size-fits-all.
If you're wondering whether a semaglutide option may be appropriate for your health goals, the first step is to speak with a licensed provider.
Ready to explore your options? Eden makes it easy to connect with a provider for safe, informed care.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/s0140-6736(21)00213-0
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183